To validate these findings at the protein level, we performed immunohistochemistry (IHC) for TAGLN on tissue arrays with glioma surgical specimens of various grades (grade 2 (n = 23), grade 3 (n = 13), and GBM (n = 45)) and normal brain tissues (n = 3). This evidence concerns the gene TAGLN and central nervous system cancer.